NCT01171729View on ClinicalTrials.gov

Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Prostatic Cancer
Interventions
BIOLOGICAL

Autologous dendritic cell

Autologous dendritic cells pulsed with prostate cancer antigen and KLH

Trial Locations (2)

410-769

National Cancer Center, Gyeonggi-do

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
collaborator

National Cancer Center, Korea

OTHER_GOV

lead

Samsung Medical Center

OTHER

NCT01171729 - Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter